In this issue:
CheckMate 901: nivolumab + cis/gem in advanced urothelial carcinoma
THOR: erdafitinib in advanced, FGFRaltered urothelial carcinoma
THOR-2: erdafitinib in BCG-treated, FGFR-altered, high-risk NMIBC
THOR cohort 2: erdafitinib in pretreated, FGFR-altered, advanced urothelial carcinoma
Radiotherapy + atezolizumab as a bladder-preserving therapy for high-risk MIBC
PCR-MIB: pembrolizumab + chemoradiation for MIBC
Treatment disparities for high-grade NMIBC
Conditional survival after radical cystectomy for urothelial bladder carcinoma
2023 European Association of Urology guidelines
Long-term outcomes in plasmacytoid variant bladder cancer
Please login below to download this issue (PDF)